AQXP - Aquinox Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
2.53
-0.12 (-4.53%)
At close: 4:00PM EDT

2.53 0.00 (0.00%)
After hours: 7:56PM EDT

Stock chart is not supported by your current browser
Previous Close2.65
Open2.67
Bid2.51 x 1000
Ask2.52 x 900
Day's Range2.51 - 2.67
52 Week Range1.96 - 16.90
Volume690,964
Avg. Volume666,728
Market Cap59.476M
Beta-18.26
PE Ratio (TTM)N/A
EPS (TTM)-2.41
Earnings DateAug 7, 2018 - Aug 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.00
Trade prices are not sourced from all markets
  • Akorn (AKRX) Looks Good: Stock Adds 7.8% in Session
    Zacks4 days ago

    Akorn (AKRX) Looks Good: Stock Adds 7.8% in Session

    Akorn (AKRX) was a big mover last session, as the company saw its shares rise more than 7% on the day, amid huge volumes.

  • Aquinox Pharmaceuticals (AQXP) Enters Oversold Territory
    Zacks7 days ago

    Aquinox Pharmaceuticals (AQXP) Enters Oversold Territory

    Aquinox Pharmaceuticals, Inc. (AQXP) has been on a bit of a cold streak lately

  • Benzinga7 days ago

    Benzinga's Daily Biotech Pulse: Acceleron On Fast Lane, OncoCyte's Accurate Diagnosis, Inspire Medical Gets Aetna Coverage

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 9) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Arrowhead Pharmaceuticals ...

  • ACCESSWIRE19 days ago

    Today’s Research Reports on Stocks to Watch: Aquinox Pharmaceuticals and Summit Therapeutics

    NEW YORK, NY / ACCESSWIRE / June 28, 2018 / Aquinox Pharmaceuticals and Summit Therapeutics both saw their shares dramatically drop on Wednesday after each company announced failed trial results. Aquinox Pharmaceuticals, Inc. shares closed down almost 85% on Wednesday and hit a new low of $2.25 on about 14.2 million shares traded. The company revealed that late-stage trial results for its bladder pain drug failed to perform better than the placebo in patients.

  • Why Sonic, National Beverage, and Aquinox Pharmaceuticals Slumped Today
    Motley Fool19 days ago

    Why Sonic, National Beverage, and Aquinox Pharmaceuticals Slumped Today

    One of these stocks plummeted nearly 85%.

  • Failed Trial Pushed Aquinox Down almost 83% This Morning
    Market Realist19 days ago

    Failed Trial Pushed Aquinox Down almost 83% This Morning

    Today, Aquinox (AQXP) announced that its late-stage investigational drug, the once-daily oral therapy rosiptor, failed to demonstrate a statistically significant benefit over placebo for IC (interstitial cystitis) or BPS (bladder pain syndrome) in the Phase 3 LEADERSHIP 301 clinical trial. Pursuant to this announcement, Aquinox stock crashed from $15.31 yesterday to $2.43 this morning. Aquinox may have to forego a $25 million of upfront payment, $60 million of development milestone payments, and $70 million of commercial milestone payments that it would have otherwise received based on its exclusive licensing agreement with Astellas Pharma.

  • TheStreet.com19 days ago

    Aquinox Pharma Shares Plunge 85% After Failed Test Results

    plummeted more than 80% Wednesday after late-stage trial results for its bladder pain drug failed to perform better than the placebo in patients. "We will be halting all further development of rosiptor," David Main, CEO of Aquinox, said in a conference call Wednesday morning. The company will also stop administering rosiptor in its trial with patients afflicted with chronic prostatitis because Aquinox does not think it will benefit them in any way, Main said.

  • Reuters19 days ago

    Aquinox to stop development of lead drug; shares plunge

    Aquinox Pharmaceuticals Inc said on Wednesday it planned to stop developing its main drug to treat bladder pain syndrome as it failed to meet the main goal of a late-stage trial, pushing its shares down as much as 85 percent. "We will be undertaking a thorough evaluation of our pipeline and other strategic options available to the company," Chief Executive Officer David Main said in a statement. Bladder pain syndrome, or interstitial cystitis, is a chronic condition characterized by bladder pressure, bladder pain and pelvic pain.

  • GlobeNewswire20 days ago

    Aquinox Announces Topline Results of Phase 3 LEADERSHIP 301 Clinical Trial in Interstitial Cystitis/Bladder Pain Syndrome

    Aquinox Pharmaceuticals, Inc. ("Aquinox") (AQXP), today announced that the Phase 3 LEADERSHIP 301 clinical trial evaluating once-daily, oral rosiptor (AQX-1125) for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS) failed to meet its primary endpoint. “This is a disappointing result for Aquinox and for patients,” said David Main, President and CEO of Aquinox.

  • GlobeNewswirelast month

    Aquinox Pharmaceuticals Announces Initiation of ProShip Phase 2 Proof-of-Concept Clinical Trial Investigating Rosiptor in CP/CPPS

    -Trial Will Enroll Approximately 100 Male Subjects in the US and Canada-. VANCOUVER, British Columbia, June 11, 2018-- Aquinox Pharmaceuticals, Inc., a clinical-stage pharmaceutical company discovering ...

  • GlobeNewswire2 months ago

    Aquinox to Present at 2018 UBS Global Healthcare Conference

    VANCOUVER, British Columbia, May 16, 2018-- Aquinox Pharmaceuticals, Inc., a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, ...

  • GlobeNewswire2 months ago

    Aquinox and Astellas Announce Exclusive Licensing Agreement for Rosiptor in the Asia-Pacific Region Including Japan

    Aquinox Pharmaceuticals, Inc. (AQXP) (“Aquinox”), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, and Astellas Pharma Inc. (TSE:4503) (“Astellas”) today announced an exclusive license agreement (“Agreement”) for Japan and certain other countries in the Asia-Pacific region for Astellas to develop and commercialize rosiptor, Aquinox’s lead drug candidate, a first-in-class, once-daily oral treatment currently in Phase 3 clinical development for interstitial cystitis/bladder pain syndrome (IC/BPS) in North America and Europe. Under the Agreement, Astellas will have the exclusive right to research, develop, and commercialize rosiptor for all human diseases and conditions in Japan and additional countries in the Asia-Pacific region, including major markets such as South Korea, Australia, Taiwan, Indonesia, and Malaysia, but excluding China and India.

  • Associated Press2 months ago

    Aquinox: 1Q Earnings Snapshot

    On a per-share basis, the Vancouver, British Columbia-based company said it had a loss of 62 cents. Aquinox shares have climbed 11 percent since the beginning of the year. The stock has fallen 6.5 percent ...

  • GlobeNewswire2 months ago

    Aquinox Pharmaceuticals Announces First Quarter 2018 Financial Results

    VANCOUVER, British Columbia, May 08, 2018-- Aquinox Pharmaceuticals, Inc., a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, ...

  • How Do Analysts See Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) Performing Over The Next Few Years?
    Simply Wall St.2 months ago

    How Do Analysts See Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) Performing Over The Next Few Years?

    The most recent earnings announcement Aquinox Pharmaceuticals Inc’s (NASDAQ:AQXP) released in December 2017 suggested company earnings became less negative compared to the previous year’s level – great news for investorsRead More...

  • GlobeNewswire2 months ago

    Aquinox to Present at Deutsche Bank 43rd Annual Healthcare Conference

    VANCOUVER, British Columbia, May 02, 2018-- Aquinox Pharmaceuticals, Inc., a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, ...

  • GlobeNewswire3 months ago

    Aquinox to Present at 2018 Bloom Burton & Co. Healthcare Conference

    VANCOUVER, British Columbia, April 26, 2018-- Aquinox Pharmaceuticals, Inc., a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory ...

  • ACCESSWIRE4 months ago

    Free Research Report as Zoetis’ Quarterly Revenues Gained 13% and Adjusted EPS Soared 47%

    Stock Monitor: Aquinox Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 26, 2018 / Active-Investors.com has just released a free earnings report on Zoetis Inc. (NYSE: ZTS ). If you want access ...

  • Associated Press4 months ago

    Aquinox reports 4Q loss

    On a per-share basis, the Vancouver, British Columbia-based company said it had a loss of 69 cents. For the year, the company reported that its loss widened to $50.2 million, or $2.14 per share. Aquinox ...

  • ACCESSWIRE4 months ago

    Aquinox Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 12, 2018 / Aquinox Pharmaceuticals, Inc. (NASDAQ: AQXP ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 12, 2018, at 4:30 PM Eastern ...

  • Reuters4 months ago

    Morning News Call - Canada, March 12

    To access the newsletter, click on the link: http://share.thomsonreuters.com/assets/newsletters/morning_News_Call/MNCGeneric_CA_03122018.pdf You can read Morning News Call Canada via TOPNEWS Canada page. ...